685 U.S. HIGHWAY ONE, 2ND FLOOR, NORTH BRUNSWICK, NJ
Enters into Clinical Collaboration to Evaluate Combination of AN4035 and Cetuximab
Results of the September 30, 2026 Extraordinary General Meeting
Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
Form of Proxy for Extraordinary General Meeting of Shareholders
Constitution
Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
No filings found
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
S-8 POS
Post-Effective Amendment to Registration Statement
Prospectus filed pursuant to Rule 424(b)(7)
Submission Upload
Correspondence